Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 231

1.

Inhibition of casein kinase II reduces TGFβ induced fibroblast activation and ameliorates experimental fibrosis.

Zhang Y, Dees C, Beyer C, Lin NY, Distler A, Zerr P, Palumbo K, Susok L, Kreuter A, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2015 May;74(5):936-43. doi: 10.1136/annrheumdis-2013-204256. Epub 2014 Jan 15.

PMID:
24431397
2.

Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis.

Tomcik M, Zerr P, Pitkowski J, Palumbo-Zerr K, Avouac J, Distler O, Becvar R, Senolt L, Schett G, Distler JH.

Ann Rheum Dis. 2014 Jun;73(6):1215-22. doi: 10.1136/annrheumdis-2012-203095. Epub 2013 May 9.

PMID:
23661493
3.

The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.

Avouac J, Palumbo-Zerr K, Ruzehaji N, Tomcik M, Zerr P, Dees C, Distler A, Beyer C, Schneider H, Distler O, Schett G, Allanore Y, Distler JH.

Arthritis Rheumatol. 2014 Nov;66(11):3140-50. doi: 10.1002/art.38819.

4.

JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis.

Dees C, Tomcik M, Palumbo-Zerr K, Distler A, Beyer C, Lang V, Horn A, Zerr P, Zwerina J, Gelse K, Distler O, Schett G, Distler JH.

Arthritis Rheum. 2012 Sep;64(9):3006-15. doi: 10.1002/art.34500.

5.

Vitamin D receptor regulates TGF-β signalling in systemic sclerosis.

Zerr P, Vollath S, Palumbo-Zerr K, Tomcik M, Huang J, Distler A, Beyer C, Dees C, Gela K, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2015 Mar;74(3):e20. doi: 10.1136/annrheumdis-2013-204378. Epub 2014 Jan 21.

PMID:
24448349
6.

Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis.

Avouac J, Palumbo K, Tomcik M, Zerr P, Dees C, Horn A, Maurer B, Akhmetshina A, Beyer C, Sadowski A, Schneider H, Shiozawa S, Distler O, Schett G, Allanore Y, Distler JH.

Arthritis Rheum. 2012 May;64(5):1642-52. doi: 10.1002/art.33501.

7.

Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis.

Reich N, Tomcik M, Zerr P, Lang V, Dees C, Avouac J, Palumbo K, Horn A, Akhmetshina A, Beyer C, Xie W, Bennett BL, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2012 May;71(5):737-45. doi: 10.1136/annrheumdis-2011-200412. Epub 2012 Jan 18.

PMID:
22258492
8.

Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma.

Sonnylal S, Denton CP, Zheng B, Keene DR, He R, Adams HP, Vanpelt CS, Geng YJ, Deng JM, Behringer RR, de Crombrugghe B.

Arthritis Rheum. 2007 Jan;56(1):334-44.

9.

Tribbles homologue 3 stimulates canonical TGF-β signalling to regulate fibroblast activation and tissue fibrosis.

Tomcik M, Palumbo-Zerr K, Zerr P, Sumova B, Avouac J, Dees C, Distler A, Becvar R, Distler O, Schett G, Senolt L, Distler JH.

Ann Rheum Dis. 2016 Mar;75(3):609-16. doi: 10.1136/annrheumdis-2014-206234. Epub 2015 Jan 20.

PMID:
25603829
10.

Alpha2-antiplasmin regulates the development of dermal fibrosis in mice by prostaglandin F(2α) synthesis through adipose triglyceride lipase/calcium-independent phospholipase A(2).

Kanno Y, Kawashita E, Kokado A, Okada K, Ueshima S, Matsuo O, Matsuno H.

Arthritis Rheum. 2013 Feb;65(2):492-502. doi: 10.1002/art.37767. Erratum in: Arthritis Rheum. 2014 Jun;66(6):1671.

11.

Activation of pregnane X receptor inhibits experimental dermal fibrosis.

Beyer C, Skapenko A, Distler A, Dees C, Reichert H, Munoz L, Leipe J, Schulze-Koops H, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2013 Apr;72(4):621-5. doi: 10.1136/annrheumdis-2012-202476. Epub 2013 Jan 4.

PMID:
23291432
12.

Sirt1 regulates canonical TGF-β signalling to control fibroblast activation and tissue fibrosis.

Zerr P, Palumbo-Zerr K, Huang J, Tomcik M, Sumova B, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2016 Jan;75(1):226-33. doi: 10.1136/annrheumdis-2014-205740. Epub 2014 Sep 1.

PMID:
25180292
13.

A novel inhibitor of Smad-dependent transcriptional activation suppresses tissue fibrosis in mouse models of systemic sclerosis.

Hasegawa M, Matsushita Y, Horikawa M, Higashi K, Tomigahara Y, Kaneko H, Shirasaki F, Fujimoto M, Takehara K, Sato S.

Arthritis Rheum. 2009 Nov;60(11):3465-75. doi: 10.1002/art.24934.

14.

Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling.

Beyer C, Zenzmaier C, Palumbo-Zerr K, Mancuso R, Distler A, Dees C, Zerr P, Huang J, Maier C, Pachowsky ML, Friebe A, Sandner P, Distler O, Schett G, Berger P, Distler JH.

Ann Rheum Dis. 2015 Jul;74(7):1408-16. doi: 10.1136/annrheumdis-2013-204508. Epub 2014 Feb 23.

PMID:
24567525
15.

S100A4 amplifies TGF-β-induced fibroblast activation in systemic sclerosis.

Tomcik M, Palumbo-Zerr K, Zerr P, Avouac J, Dees C, Sumova B, Distler A, Beyer C, Cerezo LA, Becvar R, Distler O, Grigorian M, Schett G, Senolt L, Distler JH.

Ann Rheum Dis. 2015 Sep;74(9):1748-55. doi: 10.1136/annrheumdis-2013-204516. Epub 2014 Apr 7.

PMID:
24709861
16.

Inhibition of sumoylation prevents experimental fibrosis.

Khodzhigorova A, Distler A, Lang V, Dees C, Schneider H, Beyer C, Gelse K, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2012 Nov;71(11):1904-8. doi: 10.1136/annrheumdis-2012-201746. Epub 2012 Aug 17. Erratum in: Ann Rheum Dis. 2013 Jun;72(6):1110.

PMID:
22904261
17.

CD109 overexpression ameliorates skin fibrosis in a mouse model of bleomycin-induced scleroderma.

Vorstenbosch J, Al-Ajmi H, Winocour S, Trzeciak A, Lessard L, Philip A.

Arthritis Rheum. 2013 May;65(5):1378-83. doi: 10.1002/art.37907.

18.

Activating transcription factor 3 regulates canonical TGFβ signalling in systemic sclerosis.

Mallano T, Palumbo-Zerr K, Zerr P, Ramming A, Zeller B, Beyer C, Dees C, Huang J, Hai T, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2016 Mar;75(3):586-92. doi: 10.1136/annrheumdis-2014-206214. Epub 2015 Jan 14.

PMID:
25589515
19.

Systemic sclerosis endothelial cells recruit and activate dermal fibroblasts by induction of a connective tissue growth factor (CCN2)/transforming growth factor β-dependent mesenchymal-to-mesenchymal transition.

Serratì S, Chillà A, Laurenzana A, Margheri F, Giannoni E, Magnelli L, Chiarugi P, Dotor J, Feijoo E, Bazzichi L, Bombardieri S, Kahaleh B, Fibbi G, Del Rosso M.

Arthritis Rheum. 2013 Jan;65(1):258-69. doi: 10.1002/art.37705.

20.

Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1.

Akamata K, Asano Y, Aozasa N, Noda S, Taniguchi T, Takahashi T, Ichimura Y, Toyama T, Sato S.

Arthritis Res Ther. 2014 Apr 3;16(2):R86. doi: 10.1186/ar4529.

Supplemental Content

Support Center